This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

"Anti-Aging" Pill Debuts At Groundbreaking Women's Health Conference In Washington D.C.

WASHINGTON, March 20, 2013 /PRNewswire/ -- The Academy of Women's Health will open the doors to its prestigious 21 st Annual Congress starting tomorrow in Washington, D.C., and while it will play host to some of the most renowned women's health researchers in the world, one of the most buzzed about exhibitors is SanMedica International™ LLC, distributor of SeroVital™-hgh, a revolutionary new oral human growth hormone (hGH) booster. So why all the hGH anticipation at a women's conference? Because growth hormone isn't just for men anymore. In fact, everyone from soccer moms to Hollywood A-Listers have been visiting some of the most expensive clinics in the world for controversial hGH injections due to growth hormone's touted ability to reduce wrinkles, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make you look and feel decades — not years, but DECADES — younger.

"Human growth hormone is no longer solely the province of male athletes," says Gina Daines, spokesperson for SanMedica. "Research is revealing that growth hormone is a vital aspect of women's health that could affect everything from obesity to skin and aging to sex drive."

The recent media frenzy surrounding hGH seems to underscore the importance of this hormone. It seems everyone's been talking about it; human growth hormone has been featured on The Today Show, CNN, Fox News, The Dr. Oz Show, and in Vanity Fair and Shape. And although SeroVital-hgh itself has only been available for about six months, it's already broken records in Parade magazine, been featured in Shape, on Radar Online, and on New York Live, and been touted by makeup artists in magazines like Star and OK! Even the famed Dr. Oz himself touted SeroVital's research on a recent episode of his award-winning show.

SeroVital began making headlines when the research behind it was first presented at The Obesity Society's most recent Annual Scientific Meeting in San Antonio, Texas, where a group of highly acclaimed research scientists revealed that this tiny little pill was actually capable of increasing mean, serum (blood) growth hormone levels... by an astounding 682%.

And although SanMedica is enjoying all the popular media attention it's received, the company is excited to get back to its research roots by taking SeroVital to the Women's Health Conference. "We're extremely excited to have a chance to share our research with the highly respected group of women's healthcare providers who are attending the conference," says Dr. Amy Heaton, PhD, Director of Scientific Affairs for SanMedica International who will be available at the conference to answer any questions. "The research behind SeroVital is not only revolutionary because it proves there's an oral compound capable of increasing growth hormone levels naturally — without synthetic injections — but also because it was the first clinical trial of its kind to test a compound's growth hormone boosting effects not just on young males, but on both men and women across an appropriately wide age range. We think it's important to let women's health experts know just how well women responded to the SeroVital complex."

Despite the double-blind, placebo-controlled research behind SeroVital-hgh, some skeptics are saying it sounds too good to be true. So is there a catch? Well, there are three. First, as with hGH injections, SeroVital-hgh is not a "magic bullet" but one part of a healthy lifestyle choice including a sensible diet and exercise regimen. And, just like hGH injections, you have to remember to renew your monthly supply.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,310.70 +119.33 0.69%
S&P 500 2,011.06 +8.90 0.44%
NASDAQ 4,653.6860 +15.6920 0.34%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs